2020
DOI: 10.1590/1806-9282.66.s2.22
|View full text |Cite
|
Sign up to set email alerts
|

Risk of venous thromboembolism in users of contraception and menopausal hormone therapy during the COVID-19 pandemic

Abstract: SUMMARY OBJECTIVES The outbreak of coronavirus disease (COVID-19) is a public health emergency of international concern. Inflammatory changes are part of COVID-19 pathophysiology and this might generate a higher thromboembolic risk in patients using combined hormonal contraception and menopausal hormone therapy. We aimed to discuss the main aspects related to this issue and propose management strategies for women affected by COVID-19. METHODS This narrative review collected information from several article… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0
3

Year Published

2021
2021
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 13 publications
0
6
0
3
Order By: Relevance
“…Also, the inflammatory changes are part of coronavirus disease 2019 (COVID-19) pathophysiology and this might generate a higher thromboembolic risk in patients using combined hormonal contraception and menopausal hormone therapy. The thrombosis risk of ET patients affected by COVID-19 using combined hormonal therapy should also be evaluated in this respect 24 .…”
Section: Discussionmentioning
confidence: 99%
“…Also, the inflammatory changes are part of coronavirus disease 2019 (COVID-19) pathophysiology and this might generate a higher thromboembolic risk in patients using combined hormonal contraception and menopausal hormone therapy. The thrombosis risk of ET patients affected by COVID-19 using combined hormonal therapy should also be evaluated in this respect 24 .…”
Section: Discussionmentioning
confidence: 99%
“…In a letter to the Editor sent after the publication of the article, the authors of these recommendations specify that they do not advise against the use of oestrogens, but against the use of oral oestrogens, opening the door to the possibility of using oestrogens transdermally in the case of postmenopausal women in hormonal replacement therapy (HRT) [33]. Similar recommendations have been made by other authors from other countries where COVID-19 has had very high incidence rates, such as Brazil [34]. On the contrary, the Italian Society of Contraception recommends not suspending contraceptive treatment with oestrogens in these types of patients, considering that the suspension of the oestrogen supply could accelerate the progression of COVID-19 [35].…”
Section: Patients With Mild or Asymptomatic Covid-19mentioning
confidence: 90%
“…At any rate, we feel that our findings should be taken into consideration when treating women with SHCs in the context of the COVID-19 pandemic. period of time may result in increased risk of developing deep venous thrombosis and pulmonary thromboembolism, this risk being particularly high when various combinations of risk factors come together [4,11].…”
Section: Key Pointsmentioning
confidence: 99%